Potent bromodomain and extraterminal domain inhibitor JAB-8263 suppresses MYC expression and exerts anti-tumor activity in colorectal cancer models

Figure 2 MYC signaling pathway was dose-dependently inhibited by JAB-8263 in human colorectal cancer cell lines. A-C: Multiple colorectal cancer cell lines were treated with different concentrations of JAB-8263 (1 nmol/L, 10 nmol/L and 100 nmol/L) for 16 h. Western blotting assay was performed to detect levels of MYC, p21 and p16. The expression of MYC were downregulated (A), and the expression of p21 (B) and p16 (C) were upregulated in multiple colorectal cancer cell lines.